Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹662 Cr
up ₹2.4 Cr vs Sep 2012
- Stocks held
- 22
- up 1 vs Sep 2012
- Top 10 weight
- 73.5%
- of the portfolio in its ten largest
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In October 2012 it disclosed 22 stocks worth ₹662 Cr, up ₹2.4 Cr from Sep 2012. Its largest positions were Divi's Laboratories Limited (14.5%), Cipla Limited (9.3%), Dr. Reddy's Laboratories Limited (9.3%); the ten largest together made up 73.5% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 79.3% of its equity. Cash and debt stood at 1.4%. Compared with Sep 2012 the fund entered 2 new stocks and exited 1.
Against 230 other Sectoral / Thematic funds
Concentration
94%
Top-10 weight is higher than 94% of peers
Breadth
6%
Holds more stocks than 6% of peers
Cash
18%
Holds more cash than 18% of peers
What these mean: concentration · cash
Holdings in October 2012
Download CSVEvery line the fund disclosed, with the change against Sep 2012. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Divi's Laboratories Limited | 14.48% | up 1.36 pts | ₹95.9 Cr | up ₹9.3 Cr | Added |
| Cipla Limited | 9.32% | down 0.47 pts | ₹61.7 Cr | down ₹2.9 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 9.28% | up 2.42 pts | ₹61.5 Cr | up ₹16.2 Cr | Added |
| Ranbaxy Laboratories Ltd | 7.95% | down 0.08 pts | ₹52.6 Cr | down ₹37 L | Trimmed |
| Sanofi India Limited | 7.88% | down 0.54 pts | ₹52.2 Cr | down ₹3.3 Cr | Trimmed |
| Sun Pharmaceutical Industries Limited | 5.76% | down 1.09 pts | ₹38.2 Cr | down ₹7 Cr | Trimmed |
| Zydus Lifesciences Limited | 4.97% | down 0.03 pts | ₹32.9 Cr | down ₹9 L | Held |
| Abbott India Limited | 4.71% | down 0.51 pts | ₹31.2 Cr | down ₹3.3 Cr | Trimmed |
| Indoco Remedies Limited | 4.69% | down 0.43 pts | ₹31 Cr | down ₹2.8 Cr | Trimmed |
| Sun Pharma Advanced Research Company Limited | 4.45% | up 0.25 pts | ₹29.4 Cr | up ₹1.8 Cr | Added |
| IPCA Laboratories Limited | 4.31% | down 1.41 pts | ₹28.6 Cr | down ₹9.2 Cr | Trimmed |
| GlaxoSmithKline Pharmaceuticals Limited | 4.28% | up 0.04 pts | ₹28.4 Cr | up ₹34 L | Added |
| Zydus Wellness Limited | 3.75% | up 0.20 pts | ₹24.8 Cr | up ₹1.4 Cr | Added |
| Biocon Limited | 3.58% | down 0.14 pts | ₹23.7 Cr | down ₹83 L | Trimmed |
| Aurobindo Pharma Limited | 2.87% | up 0.29 pts | ₹19 Cr | up ₹2 Cr | Added |
| Cash, TREPS & receivables | 1.33% | up 0.93 pts | ₹8.8 Cr | up ₹6.2 Cr | Added |
| Glenmark Pharmaceuticals Limited | 1.29% | up 1.29 pts | ₹8.6 Cr | up ₹8.6 Cr | New |
| Fulford India Ltd | 1.29% | down 1.70 pts | ₹8.5 Cr | down ₹11.2 Cr | Trimmed |
| Wyeth Ltd | 1.26% | down 0.17 pts | ₹8.4 Cr | down ₹1.1 Cr | Trimmed |
| Lupin Limited | 1.07% | down 0.29 pts | ₹7.1 Cr | down ₹1.9 Cr | Trimmed |
| Unichem Laboratories Limited | 0.86% | down 0.03 pts | ₹5.7 Cr | down ₹16 L | Trimmed |
| Sun Pharma Advanced Research Company Ltd | 0.50% | up 0.50 pts | ₹3.3 Cr | up ₹3.3 Cr | New |
| Vimta Labs Limited | 0.08% | down <0.01 pts | ₹56 L | down ₹1 L | Trimmed |
| Dr. Reddy'S Laboratories Ltd Debt | 0.02% | down <0.01 pts | ₹16 L | up ₹0 L | Held |
What changed, Sep 2012 to Oct 2012
New New positions (2)
- Glenmark Pharmaceuticals Limited1.3% · ₹8.6 Cr
- Sun Pharma Advanced Research Company Ltd0.5% · ₹3.3 Cr
Exited Exited (1)
- Sun Pharma Advance Research Co Ltd (Rights)was 0.4% · ₹2.6 Cr
Added Biggest additions
- Dr. Reddy's Laboratories Limitedup ₹16.2 Cr (+2.42% pts)
- Divi's Laboratories Limitedup ₹9.3 Cr (+1.36% pts)
- Aurobindo Pharma Limited
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Sep 2012, the weight rose most in Pharmaceuticals & Biotechnology (+1.9 pts) and Food Products (+0.2 pts), and fell most in Miscellaneous (−1.7 pts) and Pharmaceuticals (−0.5 pts).
- Pharmaceuticals & Biotechnology77.4% → 79.3%+1.9 pts
- Food Products3.6% → 3.8%+0.2 pts
- Miscellaneous3.0% → 1.3%−1.7 pts
- Pharmaceuticals15.9% → 15.5%−0.5 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Sep 2012 | Oct 2012 |
|---|---|---|
| Pharmaceuticals & Biotechnology | 77.4% | 79.3% |
| Pharmaceuticals | 15.9% | 15.5% |
| Food Products | 3.6% | 3.8% |
| Miscellaneous | 3.0% | 1.3% |
| Healthcare Services | 0.1% | 0.1% |
Allocation in Oct 2012change vs Sep 2012
- Pharmaceuticals & Biotechnology (14)79.3%▲ 1.9 pts
- Pharmaceuticals (5)15.5%▼ 0.5 pts
- Food Products (1)3.8%▲ 0.2 pts
- Miscellaneous (1)1.3%▼ 1.7 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Oct 2012
1.4%
▲ 0.9 pts vs Sep 2012
- Cash alone
- 1.4%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- 0.4% – 1.4%
- lowest to highest · record 1.4% in Oct 2012
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.